Johnson & Johnson $JNJ Shares Sold by Great Valley Advisor Group Inc.

by · The Cerbat Gem

Great Valley Advisor Group Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 4.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 66,617 shares of the company’s stock after selling 2,818 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in Johnson & Johnson were worth $10,176,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. GFG Capital LLC acquired a new position in Johnson & Johnson during the second quarter worth about $35,000. 1248 Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter worth approximately $48,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock worth $57,000 after acquiring an additional 150 shares during the period. Gladwyn Financial Advisors Inc. purchased a new position in Johnson & Johnson in the 2nd quarter valued at approximately $71,000. Finally, Pandora Wealth Inc. raised its holdings in Johnson & Johnson by 22.1% during the second quarter. Pandora Wealth Inc. now owns 476 shares of the company’s stock worth $73,000 after purchasing an additional 86 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.8%

Shares of NYSE JNJ opened at $211.65 on Friday. The firm has a market cap of $509.93 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 2.34 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $212.27. The firm’s 50 day moving average price is $196.09 and its 200 day moving average price is $177.08.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on JNJ shares. HSBC reissued a “buy” rating and issued a $240.00 target price on shares of Johnson & Johnson in a report on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Raymond James Financial raised their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Bank of America lifted their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Finally, Barclays increased their price target on shares of Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Four analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $206.65.

Read Our Latest Stock Analysis on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Further Reading